The text provides condensed financial statements of Pfizer Inc. and its subsidiary companies for the three months and nine months ended on September 27, 2020, and September 29, 2019. It includes summaries of the consolidated statements of income, comprehensive income, balance sheets, and equity, outlining revenues, costs, expenses, assets, liabilities, and equity. Key data include revenues, costs, net income, earnings per share, assets, liabilities, and equity, as well as details on income from continuing operations, comprehensive income, and equity transactions. In addition, it covers details on Pfizer Inc.'s various financial instruments, including debt securities, equity securities, short-term borrowings, long-term debt, and derivative financial instruments. The information encompasses the composition and amounts of these instruments, transactions such as debt issuance and retirement, and hedging activities against interest rate and foreign exchange risks. Figures on principal amounts, fair value adjustments, gains/losses recognized, and the types of financial instruments used for managing risks are also included.
The text provides an overview of Pfizer's financial performance and operations as outlined in their Quarterly Report on Form 10-Q, discussing various sections such as significant accounting policies, financial and operating segment information, cash flow analysis, and financial condition. It also covers the company's business model, global operations, strategies for growth, and recent business development initiatives like collaborations and joint ventures, aiming to sustain earnings growth and enhance shareholder value. Additionally, updates on drug applications, approvals, late-stage clinical programs, new drug candidates, and financial results are provided, revealing approvals for multiple drug applications, ongoing developments in various drugs for different indications, and the impact of factors like joint ventures, the COVID-19 pandemic, and changes in product revenues on the company's financial performance.
The text provides information stating that details required for quantitative and qualitative disclosures about market risk are referenced from the discussion in Part II, Item 7A of the company's 2019 Form 10-K, specifically under the section titled "Quantitative and Qualitative Disclosures About Market Risk - Financial Risk Management."
The text discusses the evaluation and conclusion made by the principal executive officer and principal financial officer regarding the effectiveness of the company's disclosure controls and procedures at the end of the covered period. They determined that the controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in periodic reports filed with the SEC. Additionally, there were no significant changes in the internal control over financial reporting during the most recent fiscal quarter that would materially affect the company's financial reporting.
The text provides a reference to legal proceedings by stating that the required information is included in Note 13A of Part I, Item 1 of the Quarterly Report on Form 10-Q.
The text discusses how the COVID-19 pandemic has impacted various aspects of a company's business, including operations, financial conditions, and results. It highlights the risks and challenges posed by the pandemic, such as travel limitations, manufacturing disruptions, supply chain interruptions, decreased product demand, and increased costs. The company is working on vaccine and treatment development for COVID-19 and faces uncertainties related to the success and commercial viability of their programs. The volatile global economic conditions resulting from the pandemic could further exacerbate existing risks and materially impact the company's business. Despite careful monitoring and assumptions made for operational planning and financial projections, the company cannot accurately predict the full extent of the pandemic's impact due to uncertainties surrounding future developments. The ultimate impact on the business will depend on various factors like the spread of the virus, effectiveness of vaccines and treatments, and government actions. The text also mentions the impact of the pandemic on the company's operations and financial condition and refers readers to additional sections of the quarterly report for more detailed information on the specific impacts experienced.
The provided text outlines the unregistered sales of equity securities and use of proceeds during the third quarter of 2020. It details the total number of shares purchased, the average price paid per share, and the value of shares that may yet be purchased under the plan. The purchases were made from June 29 to September 27, 2020, with a total of 44,709 shares bought at an average price of $35.90 per share. These purchases were part of a program involving common stock surrendered to the company to meet tax withholding obligations related to long-term incentive programs. For further information, refer to the Notes to Consolidated Financial Statements - Note 12. Equity in the 2019 Financial Report.
There are no defaults on senior securities according to the provided information.
The text provided states that there are no mine safety disclosures applicable.
There is no additional information provided in the text.
The text provides details about various exhibits included in a filing related to Pfizer Inc., including an amendment to a distribution agreement, an accountant acknowledgment, certifications by the CEO and CFO pursuant to the Sarbanes-Oxley Act, and XBRL instance documents. The document is signed by a senior executive on behalf of Pfizer Inc. on November 5, 2020.
